摘要
内源性非编码小分子RNA(miRNAs)参与调控多种细胞功能和生物过程,如细胞增殖、凋亡和分化等,被认为是一种新的基因表达调节因子。组织特异性的miRNAs正在成为癌症诊断的候选基因,常用来作为肿瘤早期诊断与预后的评价指标。MiRNA-128的异常表达与多种肿瘤发生、发展密切相关,预示miRNA-128有望成为肿瘤治疗的新靶点。癌细胞耐药性是影响肿瘤治疗效果的关键原因之一。本文就miRNA-128与肿瘤耐药性的关系、作用机制,以及其对肿瘤患者生存时间的影响进行综述,以期为肿瘤治疗提供新思路。
Endogenous non-coding small RNA(miRNA)is a new gene expression regulator,which is involved in the regulation of a variety of cell functions and biological processes,such as cell proliferation,apoptosis and differentiation.Tissue specific miRNAs are becoming candidate genes for cancer diagnosis,and often used as indicators for early diagnosis and prognosis of cancer.Studies have found that the abnormal expression of miRNA-128 is closely related to the occurrence and development of a variety of tumors,indicating that miRNA-128 is expected to become a new target for tumor therapy.Drug resistance of cancer cells is one of the key factors affecting the therapeutic effect of cancer.Our manuscript reviews the relationship between miRNA-128 and drug resistance of tumor,mechanism,and impact on the survival time of tumor patients,in order to provide new ideas for tumor treatment.
作者
张玉领
陈培
ZHANG Yuling;CHEN Pei(Jiangsu College of Nursing,Huai'an 223005,China)
出处
《生命的化学》
CAS
2022年第3期571-578,共8页
Chemistry of Life
基金
淮安市科技计划基金项目(HABZ201715)
江苏高校“青蓝工程”资助项目。